The stock of Agenus Inc (NASDAQ:AGEN) last traded at $0.47, down -7.58% from the previous session.
AGEN stock price is now -27.85% away from the 50-day moving average and -53.04% away from the 200-day moving average. The market capitalization of the company currently stands at $195.01M.
With the price target of $8, Robert W. Baird recently initiated with Outperform rating for Agenus Inc (NASDAQ: AGEN). On June 06, 2023, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $80, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, ARMEN GARO H, insider bought 500,000 shares of the company’s stock on Feb 15 ’24. The stock was bought for $324,050 at an average price of $0.65. Upon completion of the transaction, the insider now directly owns 625,969 shares in the company, valued at $0.29 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 15 ’23, Director WIINBERG ULF bought 25,000 shares of the business’s stock. A total of $19,000 was incurred on buying the stock at an average price of $0.76. This leaves the insider owning 124,063 shares of the company worth $58309.61. A total of 5.41% of the company’s stock is owned by insiders.
During the past 12 months, Agenus Inc has had a low of $0.47 and a high of $2.13. The fifty day moving average price for AGEN is $0.6428 and a two-hundred day moving average price translates $0.9843 for the stock.
The latest earnings results from Agenus Inc (NASDAQ: AGEN) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.13, missing analysts’ expectations of -$0.05 by -0.08. This compares to -$0.25 EPS in the same period last year. The company reported revenue of $83.8 million for the quarter, compared to $28.39 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 195.23 percent. For the current quarter, analysts expect AGEN to generate $41.46M in revenue.
